Clinical trials: Olaparib, completed
Ewing's Sarcoma
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.
- Trial name
- NCT01583543
- Testing
- Olaparib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Mesothelioma
Olaparib in People With Malignant Mesothelioma
Background: The drug olaparib may stop cancer cells from fixing damage to their deoxyribonucleic acid (DNA). It has been approved to treat certain cancers in people that were born with a mutation in the breast cancer (BRCA) gene.
- Trial name
- NCT03531840
- Testing
- Olaparib, ClinOmics
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Locally Advanced Malignant Neoplasm, Inflammatory Breast Carcinoma
Olaparib and Radiotherapy in Inoperable Breast Cancer
The majority of breast cancer patients receive radiotherapy as part of their treatment. Radiotherapy improves both locoregional control and overall survival.
- Conditions
- Locally Advanced Malignant Neoplasm, Inflammatory Breast Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02227082
- Testing
- radiotherapy, olaparib
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- The Netherlands Cancer Institute
Non Small Cell Lung Cancer
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.
- Trial name
- GOAL (NCT01513174)
- Testing
- Gefitinib, Olaparib
- Where
- 5 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Spanish Lung Cancer Group
Ovarian Cancer
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
- Trial name
- NCT00753545
- Testing
- AZD2281
- Where
- 107 sites in United States, Australia and 15 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Solid Tumours
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice…
- Trial name
- NCT02093351
- Testing
- Olaparib, Tamoxifen, Anastrozole
- Where
- 14 sites in Belgium, Denmark and 3 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Endometrial Carcinoma
Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
The primary objective of this study is to identify, in human tumour samples, biomarker changes associated to short exposure to AZD2281 as potential predictors of activity in Endometrial Carcinoma (EC).
- Trial name
- Polen (NCT02506816)
- Testing
- Olaparib
- Where
- 10 sites in Spain
- Volunteers
- 36 people
- Sponsor
- MedSIR
Cancer, Advanced Solid Malignancies
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies.
- Trial name
- NCT01813474
- Testing
- olaparib
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Malignant Solid Tumors
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
- Trial name
- NCT00516438
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Topotecan
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual…
- Trial name
- NCT04889404
- Where
- 60 sites in Japan
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline…
- Conditions
- HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations
- Trial name
- NCT03286842
- Testing
- Olaparib
- Where
- 123 sites in United States, Bulgaria and 13 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Solid Tumours
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating 3 different breakfasts (high calorie…
- Trial name
- NCT01851265
- Testing
- Olaparib, Dietary Fasted, Dietary standard
- Where
- 7 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Metastatic
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the…
- Trial name
- SAFIR02_Lung (NCT02117167)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 37 sites in France
- Volunteers
- 999 people
- Sponsor
- UNICANCER
Neoplasms, Germ Cell and Embryonal
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
This is open-label, single-arm, two-stage phase II trial of olaparib in patients with relapsed/refractory metastatic germ cell cancer. The primary objective is to evaluate the preliminary activity of Olaparib in GCT tumors.
- Trial name
- NCT02533765
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
High Grade Serous Carcinoma
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant).
- Trial name
- CAPRI (NCT03462342)
- Testing
- Olaparib Pill, AZD6738
- Where
- 3 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Pennsylvania
Triple Negative Breast Cancer
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC.
- Trial name
- DORA (NCT03167619)
- Testing
- Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Solid Tumor
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
This research study is studying a combination of targeted therapies as a possible treatment for Advanced Solid Tumors. The study interventions involved in this study are: LY2606368 Olaparib
- Trial name
- NCT03057145
- Testing
- Prexasertib, Olaparib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Geoffrey Shapiro, MD, PhD
Solid Tumours
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the effect of rifampicin on the PK parameters of olaparib in patients; Part B will allow patients continued access to olaparib after the PK…
- Trial name
- NCT01929603
- Testing
- Pharmacokinetic sampling, Rifampicin, Olaparib tablet dosing
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 32 people
- Sponsor
- AstraZeneca